Brain Cancer

Anticancer vaccine doubles time-to-disease progression, increases survival

Published in Drug Week, January 7th, 2005

A phase I study presented at the Society for Neuro-Oncology meeting using a therapeutic vaccine against malignant glioma demonstrated a doubling of time-to-disease progression and an increase in patient survival compared to historical controls.

The study was conducted by researchers at the Brain Tumor Center at the Duke Comprehensive Cancer Center and funded by the National Institutes of Health. Glioma is a devastating brain cancer that typically results in death in about a year.

Patients have few treatment options and nearly all available therapies have had minimal impact on survival. John Sampson, MD, PhD, associate professor of Neurosurgery at...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-01-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry